NCT07724184Recruiting
Revascularization of Calcified Coronary Arteries
Percutaneous Coronary Intervention of Calcified Lesions and the Use of Artificial Intelligence to Predict Successful Outcome
Source: ClinicalTrials.gov · Last updated 23 Jul 2026
Brief summary (registry, in English)
The primary aim of this study is to evaluate changes in absolute coronary flow and pressure before and after percutaneous coronary intervention in calcified lesions. The secondary aim is to use a machine learning model to predict the outcome of the intervention.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 20 Aug 2025
- Start date
- 1 Mar 2025
- Primary completion date
- 1 May 2027
- Lead sponsor
- Aalborg University Hospital
- Diseases
- Coronary artery disease
- NCT number
- NCT07724184
What you commit to
- Study type: Observational
- Planned participants: 100
- From 1 Mar 2025 to the primary completion date, 1 May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- eGFR \< 40ml/min
Other
- ACS \< 48 hours
- Patient without ability to provide informed consent
- Patient with left main stenosis
- Indication for coronary artery bypass grafting
Who the study is looking for
- Age \> 18 years
- Moderate (40-90 %) epicardial disease
- Vessel suitable for PCI and intracoronary imaging
- De novo-lesions
Age in the registry: 18 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Aalborg University Hospital Coordinator of this site? Confirm its status | Aalborg | Denmark | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.